JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 24, 2008; DOI: 10.1124/jpet.108.138529


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.138529v1
326/3/991    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Seok, Y. M.
Right arrow Articles by Kim, I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seok, Y. M.
Right arrow Articles by Kim, I.


Received for publication February 28, 2008.
Revised June 22, 2008.
Accepted for publication June 23, 2008.

Isoflavone attenuates vascular contraction through inhibition of RhoA/Rho-kinase signaling pathway

Young Mi Seok 1, Inji Baek 2, Yong-Hoon Kim 2, Yeon-Shin Jeong 2, In-Jung Lee 2, Dong Hyun Shin 2, Young Hyun Hwang 2, InKyeom Kim 1*

1 Kyungpook National University School of Medicine 2 Kyungpook National University

* Address correspondence to: E-mail: inkim{at}knu.ac.kr

Abstract

Isoflavones decrease blood pressure, improve lipid profiles, and restore vascular function. We hypothesized that isoflavone attenuates vascular contraction by inhibiting RhoA/Rho-kinase signaling pathway. Rat aortic rings were denuded of endothelium, mounted in organ baths, and contracted with U46619, a thromboxane A2 analogue or KCl 30 min after the pretreatment with genistein, daidzein or vehicle. We determined the phosphorylation level of the myosin light chain (MLC20), myosin phosphatase targeting subunit 1 (MYPT1) and protein kinase C (PKC) -potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa (CPI17) by means of the Western blot. We also measured the amount of GTP RhoA as a marker regarding RhoA activation. The cumulative additions of U46619 or KCl increased vascular tension in a concentration-dependent manner, which were inhibited by pretreatment with genistein or daidzein. Both U46619 (30 nM) and KCl (50 mM) increased MLC20 phosphorylation levels which were inhibited by genistein as well as daidzein. Furthermore, both genistein and daidzein decreased the amount of GTP RhoA activated by either U46619 or KCl. U46619 (30 nM) increased phosphorylation of the MYPT1Thr855 and CPI17Thr38, which were also inhibited by genistein or daidzein. However, neither genistein nor daidzein inhibited PDBu-induced vascular contraction and CPI17 phosphorylation. In conclusion, isoflavone attenuates vascular contraction, at least in part, through inhibition of the RhoA/Rho-kinase signaling pathway.


Key words: Isoflavones, Rho-kinase, contraction, daidzein, genistein, myosin light chain phosphatase





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.